{
    "nctId": "NCT04681287",
    "briefTitle": "Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.",
    "officialTitle": "Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "HER2 Positive Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "progression-free survival rate at 3 months\uff08PFS rate\uff09",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age: 18-75 years old female patients;\n2. The results showed that HER-2 was positive at least once in patients with recurrent and metastatic breast cancer confirmed by pathology: HER-2 (+ + +) was confirmed by immunohistochemistry; if HER-2 (+ +), fish / CISH was required to confirm HER-2 amplification;\n3. Previous treatment (including neoadjuvant, adjuvant and rescue therapy) received at least trastuzumab and TKIs;\n4. It is allowed that the previous rescue chemotherapy does not exceed 3 lines, and must be disease progression before being included in the study; it is allowed to receive rescue endocrine therapy; chemotherapy allows to receive one of the chemotherapy of albumin binding paclitaxel, vinorelbine, gemcitabine, capecitabine and aribrin;\n5. At least one target lesion can be defined according to RECIST 1.1, and the target lesion has not received radiotherapy (or other local treatment), unless it progresses after the treatment;\n6. Before the study, chemotherapy and targeted therapy must be completed for at least 2 weeks, and endocrine therapy and antiangiogenic drug treatment for 1 week;\n7. ECoG PS: 0-1 points;\n8. The expected survival time was more than 3 months;\n9. The function of the main organs is normal, that is to say, it meets the following standards:\n\n1\uff09Blood routine examination standard should meet (no blood transfusion and blood products within 14 days, not used G-CSF and other hematopoietic stimulating factors were corrected)\n\n* Hb\u226590g/L\uff1b\n\n  \u2461ANC\u22651.5\u00d7109/L\uff1b\n\n  \u2462PLT\u226575\u00d7109/L\uff1b 2\uff09Biochemical examination should meet the following standards:\n* TBIL\\<1.5\u00d7ULN\uff1b\n\n  * Alt, AST \\< 2.5 \u00d7 ULN, liver metastasis \\< 5 \u00d7 ULN;\n\n    * Bun and Cr \u2264 1 \u00d7 ULN or creatinine clearance rate \u2265 50ml / min (Cockcroft Gault formula).\n\n      10.Women of childbearing age must have a pregnancy test (serum) within 7 days before enrollment, and the results are negative, and they are willing to use appropriate contraceptive methods during the trial and within 8 weeks after the last administration of the trial drug; 11.The subjects volunteered to join the study, signed the informed consent form, had good compliance and cooperated with the follow-up.\n\nExclusion Criteria:\n\n1. Symptomatic, uncontrolled brain metastases or leptomeningeal metastases.However, patients with stable condition after local treatment for 4 weeks could be enrolled;\n2. There was effusion in the third space which could not be controlled by drainage or air pressure;\n3. Interstitial lung disease, non-infectious pneumonia, memory pneumonia, pulmonary fibrosis and other diseases;\n4. Those who have a history of live attenuated vaccine vaccination in the 28 days before the first study medication or are expected to receive live attenuated vaccine in the study;\n5. Other malignant tumors in the past 3 years, excluding cervical carcinoma in situ, basal cell carcinoma of skin or squamous cell carcinoma of skin;\n6. Patients with hypertension who could not be reduced to normal range after antihypertensive drug treatment (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg);\n7. Suffering from serious or uncontrollable diseases, including but not limited to:\n\n1) Active viral infection, such as HIV, HBV active phase (HBsAg positive and HBV-DNA \u2265 103, hepatitis C antibody positive); 2) Previous severe cardiovascular diseases: uncontrollable hypertension; myocardial infarction, unstable arrhythmia, congestive heart failure, pericarditis, myocarditis, etc. in the first six and six patients; according to NYHA standard, grade III \\~ IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) \\< 50% according to NYHA standard; 8.Patients with a history of psychotropic substance abuse and unable to quit or with mental disorders; 9.According to the judgment of the researchers, there are other patients with accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study; 10.Pregnant or lactating women; 11.The researchers think it is not suitable for the participants.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}